This dataset contains summary data visualizations and clinical data from a broad sampling of 487 lung squamous cell carcinomas from 487 patients. The data was gathered as part of the PanCancer Atlas initiative, which aims to answer big, overarching questions about cancer by examining the full set of tumors characterized in the robust TCGA dataset. The clinical data includes mutation count, information...

This dataset contains summary data visualizations and clinical data from the targeted sequencing of 10,000 clinical cases using the MSK-IMPACT assay. The clinical data includes mutation count, information about mutated genes, tumor mutational burden calculations, tissue site from which the sample was derived, tumor purity among other relevant data points. The data set also includes copy-number segment...

This dataset contains summary data visualizations and clinical data from a broad sampling of HER2- and HER3-mutant tumors. The data was generated utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, Amplification Status, Best objective response rate, Bubble...

This dataset contains summary data visualizations and clinical data from a broad 183 samples of thoracic tumors from 77 patients. The data was generated by the Charles Rudin Lab, utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, patient demographics,...

TCGA Lung Squamous Cell Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional. This dataset contains summary data visualizations and clinical data from a broad sampling of 511 carcinomas from 511 patients. The data was gathered as part of the Broad Institute of MIT and Harvard Firehose initiative, a cancer analysis pipeline. The clinical data includes mutation count, information...

Summary from the GEO: "Immune checkpoint blockade (ICB) has demonstrated significant promise for the treatment of advanced malignancies. Anti-CTLA4 and ant-PD1 therapy can activate the immune system and result in durable control in diseases such as melanoma and non-small cell lung cancer. 109 RNASeq samples (58 On-treatment and 51 Pre-treatment) from 65 patients." Abstract from the publication that...

This dataset contains the summary data visualizations and clinical data of targeted sequencing of 248 samples from 124 patients' cfDNA/WBC[White Blood Cell] and tumor/normal pairs. Clinical data includes: Cancer Type, Mutation Count, Age, Tumor Type, cfDNA TMB, Collapsed fragment mean coverage, Collapsed mean coverage, ctDNA Fraction, MSI Score, Oncotree Code, cfDNA/Tumor Sample Class, Tumor Tissue...

This dataset contains the summary data visualizations and clinical data from targeted sequencing of 915 samples from 860 patients with metastatic lung adenocarcinoma. Clinical data includes: Number of Samples Per Patient, Mutation Count, Fraction Genome Altered, Diagnosis Age, Sex, Primary/Metastasis Sample Type, Chemotherapy, Clinical Trial, Driver Mutations, Durable Clinical Benefit, Gene Panel,...

This dataset contains the summary data visualizations and clinical data from whole-exome sequencing of 75 tumor/normal NSCLC pairs treated with PD-1 plus CTLA-4 blockade from 75 patients. Clinical data includes: Mutation Count, Sex, Histology, Age (yrs), Best Overall Response, Durable Clinical Benefit, ECOG performance status, HLA_A1 allele, HLA_A2 alleles, HLA_B1 alleles, HLA_B2 alleles, HLA_C1 alleles,...

This dataset contains the summary data visualizations and clinical data from IMPACT sequencing of 240 NSCLC tumor/normal pairs treated at MSKCC with anti-PD-(L)1 based therapy from 240 patients. Clinical data includes: Cancer Type, Mutation Count, Fraction Genome Altered, Sex, Durable Clinical Benefit, FGA, Gene Panel, IRB, Lines of treatment, Mutation Rate, Oncotree Code, PD-L1 Score (%), Smoker,...